pntd.0011910.s002.xlsx (34.66 kB)

Clinical and diagnostic features of patients from Group 4.

dataset

posted on 2024-01-18, 18:41 authored by Manuel Abal, Virginia Balouz, Rosana Lopez, M. Eugenia Giorgi, Carla Marino, Cintia V. Cruz, Jaime Altcheh, Carlos A. Buscaglia

History

Usage metrics

Keywords

trypomastigotes surface coat technical difficulties associated protective antibody response previous studies indicated patient negative seroconversion linked immunosorbent assay included 39 non bsa scaffold decorated 83 months ];3 groups based >- infected mothers retrospective cohort study gal antigenic surrogate elisa may assist vs 60 months conventional serological tests >- infected children trypanosoma cruzi 4 %), α conventional serological methods 3 %) patients >- infected serological responses conventional serology vs 43 treated children parasitological tests cruzi infected infants infected individuals group 4 5 months 4 years 36 months 23 months 3 years 3 days xlink ">treatment initiation treatment evaluation tools evaluated therapeutic responses therapeutic marker termed ngp synthetic α successful treatment suboptimal seroprevalence straightforward post shorten follow several units routine implementation proper evaluation prolonged persistence p novel tool neoglycoprotein consisting ic 95 house enzyme higher rate herein developed every group disappears soon diagnostic needs detailed analysis control cohort chagas disease analyzed separately 31 days 26 days 16 years

Licence

CC BY 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

Clinical and diagnostic features of patients from Group 4.

History

Usage metrics

Categories

Keywords

Licence

Exports